Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
Reqorsa® Therapy May Be Potential Treatment for ALK-Positive Lung Cancer
Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Related news for (GNPX)
- Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
- 24/7 Market News Snapshot 23 October, 2025 – Genprex, Inc. Common Stock (NASDAQ:GNPX)
- MoBot alert highlights: NASDAQ: TNGX, NYSE: BATL, NASDAQ: TELO, NASDAQ: VTYX, NASDAQ: GNPX (10/23/25 07:00 AM)
- MoBot alert highlights: NASDAQ: TDIC, NASDAQ: GNPX, NASDAQ: TAOP, NASDAQ: ACHV, NASDAQ: ELBM (10/17/25 08:00 AM)
- Biotech, Batteries & BioSilk—Bold Breakouts